MBM-17 is a potent inhibitor of NIMA-related kinase 2 (Nek2,IC50 of 3 nM). It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.
MBM-17S, a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 3 nM, effectively inhibits cancer cell proliferation by inducing cell cycle arrest and apoptosis. It demonstrates antitumor activities without evident toxicity to mice.
CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase E
JH295 is a highly potent and selective inhibitor of NIMA-related kinase 2 (Nek2), exhibiting irreversible inhibition activity with an IC 50 value of 770 nM. This compound effectively inhibits cellular Nek2 using the alkylation of Cys22. Importantly, JH295 does not exhibit any inhibitory effects toward Cdk1, Aurora B, or Plk1, which are kinases involved in mitotic processes. Furthermore, JH295 has no impact on bipolar spindle assembly or the spindle assembly checkpoint mechanism.